Spotlight On ATTR-CM

Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.

LikeLikedUnlike

Episodes 16-20 of 20

Understanding the Pathophysiology Behind ATTR-CM
Heart Matters
Understanding the Pathophysiology Behind ATTR-CM
- Frederick Ruberg, MD
  Peer
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Heart Matters
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
- Kibum Kim, PhD
  Peer
ATTR-CM Screening: How Economic Factors Can Impact Care
Heart Matters
ATTR-CM Screening: How Economic Factors Can Impact Care
- Kibum Kim, PhD
  Peer
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CM
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CM
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
advertisement